Positive Outlook for Akero Therapeutics Driven by Efruxifermin’s Potential and Strategic Clinical Programs

TIPRANKS
11 Nov 2024
Akero Therapeutics-3.73%Post-market

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price targe...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."